QQQ   355.29 (+0.61%)
AAPL   181.68 (+0.61%)
MSFT   327.94 (+0.82%)
META   265.65 (+0.40%)
GOOGL   122.93 (+0.65%)
AMZN   124.01 (-0.19%)
TSLA   245.91 (+4.70%)
NVDA   391.05 (+1.55%)
NIO   7.93 (+1.80%)
BABA   86.19 (+0.06%)
AMD   124.88 (+3.16%)
T   16.00 (-0.44%)
F   13.81 (+1.69%)
MU   65.44 (+0.18%)
CGC   0.67 (-3.39%)
GE   106.05 (-0.02%)
DIS   91.97 (-0.61%)
AMC   4.74 (+1.28%)
PFE   38.92 (-0.43%)
PYPL   63.86 (-0.59%)
NFLX   425.30 (+3.89%)
QQQ   355.29 (+0.61%)
AAPL   181.68 (+0.61%)
MSFT   327.94 (+0.82%)
META   265.65 (+0.40%)
GOOGL   122.93 (+0.65%)
AMZN   124.01 (-0.19%)
TSLA   245.91 (+4.70%)
NVDA   391.05 (+1.55%)
NIO   7.93 (+1.80%)
BABA   86.19 (+0.06%)
AMD   124.88 (+3.16%)
T   16.00 (-0.44%)
F   13.81 (+1.69%)
MU   65.44 (+0.18%)
CGC   0.67 (-3.39%)
GE   106.05 (-0.02%)
DIS   91.97 (-0.61%)
AMC   4.74 (+1.28%)
PFE   38.92 (-0.43%)
PYPL   63.86 (-0.59%)
NFLX   425.30 (+3.89%)
QQQ   355.29 (+0.61%)
AAPL   181.68 (+0.61%)
MSFT   327.94 (+0.82%)
META   265.65 (+0.40%)
GOOGL   122.93 (+0.65%)
AMZN   124.01 (-0.19%)
TSLA   245.91 (+4.70%)
NVDA   391.05 (+1.55%)
NIO   7.93 (+1.80%)
BABA   86.19 (+0.06%)
AMD   124.88 (+3.16%)
T   16.00 (-0.44%)
F   13.81 (+1.69%)
MU   65.44 (+0.18%)
CGC   0.67 (-3.39%)
GE   106.05 (-0.02%)
DIS   91.97 (-0.61%)
AMC   4.74 (+1.28%)
PFE   38.92 (-0.43%)
PYPL   63.86 (-0.59%)
NFLX   425.30 (+3.89%)
QQQ   355.29 (+0.61%)
AAPL   181.68 (+0.61%)
MSFT   327.94 (+0.82%)
META   265.65 (+0.40%)
GOOGL   122.93 (+0.65%)
AMZN   124.01 (-0.19%)
TSLA   245.91 (+4.70%)
NVDA   391.05 (+1.55%)
NIO   7.93 (+1.80%)
BABA   86.19 (+0.06%)
AMD   124.88 (+3.16%)
T   16.00 (-0.44%)
F   13.81 (+1.69%)
MU   65.44 (+0.18%)
CGC   0.67 (-3.39%)
GE   106.05 (-0.02%)
DIS   91.97 (-0.61%)
AMC   4.74 (+1.28%)
PFE   38.92 (-0.43%)
PYPL   63.86 (-0.59%)
NFLX   425.30 (+3.89%)
NASDAQ:IMRX

Immuneering (IMRX) Stock Forecast, Price & News

$10.60
+0.34 (+3.31%)
(As of 01:28 PM ET)
Compare
Today's Range
$10.08
$10.84
50-Day Range
$6.49
$13.36
52-Week Range
$3.70
$16.17
Volume
22,723 shs
Average Volume
59,280 shs
Market Capitalization
$310.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.67

Immuneering MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
76.1% Upside
$18.67 Price Target
Short Interest
Bearish
7.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.15) to ($2.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

716th out of 986 stocks

Pharmaceutical Preparations Industry

339th out of 480 stocks


IMRX stock logo

About Immuneering (NASDAQ:IMRX) Stock

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.

Receive IMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter.

IMRX Stock News Headlines

Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
This Stock's Worth Researching
Uncover the buzz behind this trending stock. Read the comprehensive report here.
Mizuho Upgrades Immuneering Corp (IMRX)
Immuneering (NASDAQ:IMRX) PT Raised to $22.00
Immuneering (IMRX) was upgraded to a Hold Rating at Morgan Stanley
Immuneering (NASDAQ:IMRX) Upgraded at Morgan Stanley
Immuneering (NASDAQ:IMRX) Stock Rating Upgraded by Mizuho
Immuneering (IMRX) was upgraded to a Buy Rating at Mizuho Securities
Immuneering (NASDAQ:IMRX) Now Covered by Mizuho
Immuneering (IMRX) Receives a New Rating from Mizuho Securities
See More Headlines

IMRX Price History

IMRX Company Calendar

Last Earnings
11/08/2021
Today
6/09/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMRX
Fax
N/A
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.67
High Stock Price Forecast
$22.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+77.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-50,510,000.00
Net Margins
-15,934.70%
Pretax Margin
-38,512.78%

Debt

Sales & Book Value

Annual Sales
$320,000.00
Book Value
$4.16 per share

Miscellaneous

Free Float
22,258,000
Market Cap
$307.42 million
Optionable
Not Optionable
Beta
-1.35

Key Executives

  • Dr. Benjamin J. Zeskind M.B.A. (Age 39)
    MBA, Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $839.77k
  • Dr. Brett M. Hall Ph.D. (Age 54)
    Chief Scientific Officer
    Comp: $819.69k
  • Ms. Mallory Morales CPA (Age 39)
    VP of Fin., Principal Financial & Accounting Officer and Treasurer
  • Ms. Paula George CPA
    Sr. Mang. of Accounting & Operations
  • Mr. Michael D. Bookman J.D. (Age 34)
    Gen. Counsel & Sec.
  • Ms. Leah R. Neufeld
    Chief People Officer
  • Dr. Scott Barrett M.D. (Age 59)
    Chief Medical Officer
  • Dr. Mohamedi Kagalwala M.B.A.
    Ph.D., Head of Neuroscience Devel.
  • Dr. Peter King Ph.D.
    Head of Discovery & VP
  • Dr. Rajaraman Krishnan Ph.D.
    Head of Neuroscience Discovery













IMRX Stock - Frequently Asked Questions

Should I buy or sell Immuneering stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMRX shares.
View IMRX analyst ratings
or view top-rated stocks.

What is Immuneering's stock price forecast for 2023?

3 Wall Street research analysts have issued 1 year price targets for Immuneering's shares. Their IMRX share price forecasts range from $14.00 to $22.00. On average, they anticipate the company's share price to reach $18.67 in the next year. This suggests a possible upside of 77.6% from the stock's current price.
View analysts price targets for IMRX
or view top-rated stocks among Wall Street analysts.

How have IMRX shares performed in 2023?

Immuneering's stock was trading at $4.85 at the start of the year. Since then, IMRX stock has increased by 116.7% and is now trading at $10.51.
View the best growth stocks for 2023 here
.

Are investors shorting Immuneering?

Immuneering saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,570,000 shares, an increase of 25.6% from the April 30th total of 1,250,000 shares. Based on an average daily trading volume, of 65,400 shares, the days-to-cover ratio is currently 24.0 days. Currently, 7.4% of the shares of the company are short sold.
View Immuneering's Short Interest
.

When is Immuneering's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our IMRX earnings forecast
.

How were Immuneering's earnings last quarter?

Immuneering Co. (NASDAQ:IMRX) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.10. The business had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.70 million. Immuneering had a negative trailing twelve-month return on equity of 44.23% and a negative net margin of 15,934.70%.

When did Immuneering IPO?

(IMRX) raised $105 million in an IPO on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as the underwriters for the IPO.

What is Immuneering's stock symbol?

Immuneering trades on the NASDAQ under the ticker symbol "IMRX."

Who are Immuneering's major shareholders?

Immuneering's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (11.82%), BlackRock Inc. (4.58%), FMR LLC (1.38%), ExodusPoint Capital Management LP (0.30%), Susquehanna International Group LLP (0.20%) and Jane Street Group LLC (0.16%). Insiders that own company stock include Ann E Berman, Benjamin J Zeskind, Biren Amin, Brett Matthew Hall, Laurie Keating, Michael Bookman and Scott Barrett.
View institutional ownership trends
.

How do I buy shares of Immuneering?

Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immuneering's stock price today?

One share of IMRX stock can currently be purchased for approximately $10.51.

How much money does Immuneering make?

Immuneering (NASDAQ:IMRX) has a market capitalization of $307.42 million and generates $320,000.00 in revenue each year. The company earns $-50,510,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis.

How can I contact Immuneering?

The official website for the company is www.immuneering.com. The company can be reached via phone at 617-500-8080 or via email at afields@rxir.com.

This page (NASDAQ:IMRX) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -